Industry Briefs: May 28, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 28, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Research has expanded its existing hot-melt extrusion capacity with the addition of an 18-mm Leistritz twin-screw mixer/extruder. Read More

Bristol-Myers Squibb formed the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Read More

FEI has launched its Living Lab for structural biology research on the campus of the National Institutes of Health. Read More

Mylan and Sunovion have entered into settlement agreements in the companies’ litigation relating to generic Brovana (arformoterol tartrate) and Xopenex (levalbuterol hydrochloride).

Recipharm secures financing for a EUR 90-million ($112 million) loan facility for further acquisition of niche CDMOs, investment in existing facilities, and building long-term partnerships with major pharmaceuticals companies. Read More

People News

Amgen has announced that Kevin W. Sharer has retired from his post as CEO and the company’s board of directors has appointed Robert A. Bradway his replacement. Read More

DSM has appointed Laura Parks as president and business unit director of finished-dosage business. Read More

Onyx Scientific has appointed Brian Jolly as its European business development director. Read More

Pfizer has named Olivier Brandicourt as president and general manager of its emerging markets and established products business units. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here